Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TWINSS phase 2 trial of subcutaneous iscalimab in Sjögren syndrome
MOH_2019-07-30_007224Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of iscalimab in Sjögren's syndrome (4 arms), sponsored by Novartis. Started Jun 2019; status: active, not recruiting.
02
Drugs
iscalimab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on MOH_2019-07-30_007224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-07-30_007224.